Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
GH Research ( (GHRS) ) has provided an announcement.
GH Research PLC announced on May 13, 2026, that it will attend the American Psychiatric Association Annual Meeting in San Francisco, California. The conference is scheduled to take place from May 16 to May 20, 2026, and the company’s participation underscores its engagement with leading clinicians and researchers in psychiatric care, potentially supporting its visibility and relationships within the mental health treatment landscape.
The most recent analyst rating on (GHRS) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page.
Spark’s Take on GHRS Stock
According to Spark, TipRanks’ AI Analyst, GHRS is a Neutral.
The score is held back primarily by weak financial performance (no revenue, widening losses, and ongoing cash burn), partly offset by a strong, low-leverage balance sheet. Technicals are supportive with clear upward trend and positive momentum, while valuation remains a drag due to negative earnings and no dividend.
To see Spark’s full report on GHRS stock, click here.
More about GH Research
GH Research PLC is an Ireland-based biopharmaceutical company focused on developing treatments in the field of psychiatry. The company targets mental health disorders, positioning itself within the broader neuropsychiatric therapeutics market and engaging closely with the psychiatric clinical and research community.
Average Trading Volume: 218,174
Technical Sentiment Signal: Buy
Current Market Cap: $1.48B
For detailed information about GHRS stock, go to TipRanks’ Stock Analysis page.